Immunovant’s Clinical Trial Reveals Potential of IMVT-1402: Consistent IgG Reduction and Favorable Safety Data in Phase 1 Study
Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that subcutaneously administered doses of IMVT-1402 produced